Although activation of the IFN signature is generally thought to be tumor-suppressive (Chan et al., 2012; Snell et al., 2017), our and other studies suggest that IFN-related signaling pathways function as double-edged swords in cancer (Forys et al., 2014; Snell et al., 2017). The gene discussed is IFNA1; the disease is cancer.